Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous MAGE-A3/A6-specific TCR gene-engineered lymphocytes KITE-718

Human autologous T lymphocytes genetically modified to express a T-cell receptor (TCR) that specifically targets human melanoma-associated antigen A3 (MAGE-A3) and MAGE-A6 (MAGEA3/A6; MAGE-A3/A6), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with a gene expressing a TCR specific for the MAGE-A3/A6 antigens, expanded ex vivo, and reintroduced into the patient. Then, the autologous MAGE-A3/A6-specific TCR gene engineered lymphocytes KITE-718 target and bind to tumor cells expressing the MAGE-A3 and/or MAGE-A6 antigens. This halts the growth of and kills MAGE-A3/A6-expressing cancer cells. The tumor-associated antigens MAGE-A3 and MAGE-A6 are overexpressed on a variety of tumor cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-MAGE-A3/A6 TCR-transduced T cells KITE-718
MAGE-A3/A6 T cell receptor engineered T cells
MAGE-A3/A6 T cell receptor engineered T cells KITE-718
MAGE-A3/A6 TCR engineered T lymphocytes
MAGEA3/A6-targeted TCR-transduced T cells KITE-718
TCR-transduced autologous T cells KITE-718
Code name:KITE 718
KITE-718
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search